Tarsus Pharmaceuticals Inc (TARS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($18.26 Million) by net assets ($335.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tarsus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Tarsus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TARS total liabilities for a breakdown of total debt and financial obligations.
Tarsus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Jingcheng Copper Share Co Ltd
SHE:002171
|
-0.009x |
|
Beijing Orient Landscape Co Ltd
SHE:002310
|
0.009x |
|
Ansell Ltd
AU:ANN
|
0.053x |
|
CESC Limited
NSE:CESC
|
0.119x |
|
Cargotec Oyj
HE:CGCBV
|
0.087x |
|
Scorpio Tankers Inc.
F:S0QA
|
0.044x |
|
Sinocelltech Group Ltd
SHG:688520
|
0.137x |
|
Seadrill Limited
NYSE:SDRL
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Tarsus Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Tarsus Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see TARS company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $224.53 Million | $-83.03 Million | -0.370x | +38.00% |
| 2023-12-31 | $196.99 Million | $-117.49 Million | -0.596x | -134.66% |
| 2022-12-31 | $192.90 Million | $-49.03 Million | -0.254x | -1230.69% |
| 2021-12-31 | $166.73 Million | $3.75 Million | 0.022x | +117.65% |
| 2020-12-31 | $165.98 Million | $-21.14 Million | -0.127x | -120.82% |
| 2019-12-31 | $-6.00 Million | $-3.67 Million | 0.612x | -29.99% |
| 2018-12-31 | $-1.35 Million | $-1.18 Million | 0.874x | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing T… Read more